Revolutionizing Biologics Manufacturing: The Bioprocessing Summit Offers Dedicated Cell and Gene Therapy Streams

Global Event in Boston, August 12-16, Provides New Data,
Technologies, and Collaboration Opportunities

BOSTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/BPSMT?src=hash" target="_blank"gt;#BPSMTlt;/agt;–With cell and gene therapies revolutionizing cancer treatment, curing
major diseases with a single administration, and commanding blockbuster
prices, biologics manufacturers are clamoring to move the “next big
drug” into the marketplace.

To help biomanufacturers meet patient demand, while addressing quality,
safety, and cost-efficiency challenges, The
Bioprocessing Summit from Cambridge Healthtech Institute will
feature 60+ presentations across two dedicated week-long conference
tracks on Cell Therapy Manufacturing and Gene Therapy Manufacturing.
Taking place August 12-16, 2019 at the Seaport World Trade Center,
Boston, this premier global conference will bring together 1,500
scientists, engineers, and leaders from biotechnology and pharmaceutical
companies, academia, and government.

“The clinical data supporting cell and gene therapies is outstanding.
However, robust analytical and manufacturing strategies will determine
the long-term success of this industry and supply of such cutting-edge
therapies to patients. The Cell and Gene Therapy CMC and Manufacturing
tracks at The Bioprocessing Summit will give scientists access to new
analytical and manufacturing data, technologies, and contacts to
capitalize on a new era,” said Dan Barry, Senior Conference Director for
these tracks at The Bioprocessing Summit.

The Cell and Gene Therapy CMC and Manufacturing streams will be part of
16 separate meetings and more than 200 presentations at the event.

Cell Therapy CMC and Manufacturing sessions will explore regulatory and
CMC strategies, product and process characterization, automation, and
autologous and allogeneic manufacturing for CAR Ts, and next-generation
therapies.

Gene Therapy CMC and Manufacturing sessions will focus on viral
vector-based gene therapies. Topics will include impurity analysis,
potency assay development, process development, scale-up, clinical and
commercial manufacturing, purification, and formulation.

The Bioprocessing Summit will also include new opportunities for
one-on-one networking, an Exhibit Hall featuring 110-plus cutting-edge
innovators, poster sessions, and more. See bioprocessingsummit.com.

About Cambridge Healthtech Institute
Cambridge
Healthtech Institute (CHI), a division of Cambridge Innovation
Institute, is the preeminent life science network for leading
researchers and business experts from top pharmaceutical, biotech, CROs,
academia, and niche service providers. CHI is renowned for its vast
conference portfolio held worldwide including PepTalk, Molecular
Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo,
PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World
Preclinical Congress, The Bioprocessing Summit, Next Generation Dx
Summit, Immuno-Oncology Summit, and Discovery on Target. CHI’s portfolio
of products include Cambridge Healthtech Institute Conferences, Barnett
International, Insight Pharma Reports, Bio-IT World, Clinical
Research News, and Diagnostics World.

Contacts

Dawn Ringel
[email protected]